Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
JAZZ · Nasdaq · United States · Pharmaceutical Preparations
In shortJazz Pharmaceuticals plc is loss-making, generates cash and carries moderate debt, with revenue growing (+4.9% last year).
Financial health
Mixed
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -10.1% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -8.3% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -8.5% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -2.5% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.86× | 88/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 1.24× | 42/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | – | n/a |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | – | n/a |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 1.63 | 14/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 30.4% | 100/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 5 of 5 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 2 of 5 | 40/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 5 | 100/100 |
| Revenue growth volatility | 11.5% | 69/100 |
| Operating margin volatility | 11.6% | 4/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 5.3% | 46/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 3,094 | 3,659 | 3,834 | 4,069 | 4,268 |
| Research & development | 506 | 590 | 850 | 884 | 783 |
| Selling, general & admin | 1,452 | 1,417 | 1,343 | 1,385 | 1,809 |
| Operating income | 170 | (66) | 579 | 717 | (430) |
| Interest expense | 90 | 33 | 33 | – | – |
| Pre-tax income | (113) | (373) | 298 | 470 | (628) |
| Income tax | 216 | (159) | (120) | (91) | (272) |
| Net income | (330) | (224) | 415 | 560 | (356) |
| Diluted EPS | −$5.52 | −$3.58 | $6.10 | $8.65 | −$5.84 |
| Diluted shares (millions) | 60 | 63 | 72 | 66 | 61 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
1.63 Grey zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
5/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 3, 2026